The social value of lecanemab for patients with early Alzheimer's disease in Japan.

待确认 10 由 doctorslh 发布于 2026/5/14 15:43:57

DOI:10.1177/13872877261447312
作者：Ataru Igarashi,?Mie Azuma-Kasai,?Mayaka Tani,?Takuro Utsumi,?Hidetoshi Shibahara,?Sachie Inoue,?Simon Rothwell,?Gaku Kamanaka,?Yukinori Sakata,?Hironobu Hiyoshi,?Kiyoyuki Tomita
文献类型：期刊论文
补充材料：只需要正文

Sage

Abstract：BackgroundLecanemab is the first approved disease-modified therapy in Japan for patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (AD-D).Objec

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

9小时前

离异带俩喷火龙王

9bd30cb14f6f11f184b334735aa3bc31.pdf

10小时前

Book学术机器人

2026/5/14 15:43:57 未找到该文献，机器人已退出，请等待人工下载

2026/5/14 15:43:57 Book学术AI机器人收到请求，开始寻找文献

2026/5/14 15:43:57 已向机器人发送请求

10小时前

doctorslh 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库State-Of-The-Art Structural Regulation Methods and Quantum Chemistry for Carbon-Based Single-Atom Catalysts in Advanced Oxidation Process: Critical Perspectives into Molecular Level